Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23162299 | 0.91 | CYP3A4 (0.40) | CSF1RDGAT1KDM4ENR1I2HIF1A | |
| SCHEMBL28959853 | 0.91 | CSF1R (0.34) | CSF1RDGAT1KDM4ENR1I2HIF1A | |
| SCHEMBL20564345 | 0.91 | HIF1A (0.38) | CSF1RDGAT1HIF1AALDH1A1GAA | |
| SCHEMBL23162278 | 0.90 | AAK1 (0.39) | CSF1RDGAT1KDM4ENR1I2HIF1A | |
| SCHEMBL22726537 | 0.89 | NR1I2 (0.37) | CSF1RDGAT1KDM4ENR1I2HIF1A | |
| SCHEMBL20562111 | 0.86 | CA1 (0.44) | CSF1RDGAT1KDM4ENR1I2CA1 | |
| SCHEMBL26110064 | 0.86 | CYP3A4 (0.42) | CSF1RDGAT1NR1I2CA1CA2 | |
| SCHEMBL27452294 | 0.84 | CSF1R (0.38) | CSF1RDGAT1KDM4ENR1I2CA1 | |
| SCHEMBL516806 | 0.81 | AAK1 (0.39) | DGAT1KDM4EHIF1ACA1CA2 | |
| SCHEMBL515152 | 0.81 | ROCK1 (0.40) | DGAT1HIF1ACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085053-A1 | BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2026-03-26 | — | — | US | disclosed |
| US-12391679-B2 | Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases | ONCO3R THERAPEUTICS BV (BE) | 2025-08-19 | — | — | US | disclosed |
| US-20250195484-A1 | CEREBLON LIGANDS AND USES THEREOF | UNIV MICHIGAN (US) | 2025-06-19 | — | — | US | disclosed |
| US-12065443-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2024-08-20 | — | — | US | disclosed |
| EP-3976189-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2024-07-03 | — | — | EP | disclosed |
| EP-3976189-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023183607-A1 | CEREBLON LIGANDS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183607-A1 | CEREBLON LIGANDS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20220340581-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-10-27 | — | — | US | disclosed |
| US-20220340548-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-10-27 | — | — | US | disclosed |
| US-11339166-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2022-05-24 | — | — | US | disclosed |
| US-11339166-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | GALAPAGOS NV (BE) | 2022-05-24 | — | — | US | disclosed |
| EP-3717471-B1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2022-01-05 | — | — | EP | disclosed |
| US-20210101903-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2021-04-08 | — | — | US | disclosed |
| WO-2020239658-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | GALAPAGOS NV (BE) | 2020-12-03 | — | — | WO | disclosed |
| EP-3717471-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | Galapagos NV (BE) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195484-A1 | CEREBLON LIGANDS AND USES THEREOF | CRBN, CDR2, CHLSN | CSF1R 646/4885DGAT1 4664/4885KDM4E 2661/4885 |
| US-11339166-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | F12, F3, COL1A1 | CSF1R 285/4885DGAT1 3459/4885KDM4E 4198/4885 |
| US-20260085053-A1 | BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF | SIK1, CHUK, SIK2 | CSF1R 1450/4885DGAT1 3395/4885KDM4E 2280/4885 |
| US-20220340548-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | IL1B, IL1A, IL36G | CSF1R 288/4885DGAT1 3594/4885KDM4E 3891/4885 |
| US-12065443-B2 | Compounds and pharmaceutical compositions thereof for the treatment of diseases | F12, F3, COL1A1 | CSF1R 285/4885DGAT1 3459/4885KDM4E 4198/4885 |
| US-20220340581-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | F12, F3, COL1A1 | CSF1R 285/4885DGAT1 3459/4885KDM4E 4198/4885 |
| US-20210101903-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES | JAK3, IFNG, IL23R | CSF1R 243/4885DGAT1 3568/4885KDM4E 4114/4885 |
| US-12391679-B2 | Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases | IL5, IL15, IL1A | CSF1R 290/4885DGAT1 4781/4885KDM4E 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.